Capricor Therapeutics closed at $8.92 on Nov 4, up 8.25%, 74.8% below its 52-week closing high. Volume of 6.4M shares was 2.34× its 20-day average (well above normal).
Split-adjusted performance: +15.1% over one month, -74.1% over six months.
Short interest was 19.9M shares at the Oct 15 settlement, up 5.5% from the prior report (48.4% of float, 6.6 days to cover).
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy.
What is CAPR's market cap?
$518.60M, based on the Nov 4 close of $8.92.
Does Capricor Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CAPR is sold short?
19.9M shares, 48.4% of float, as of Oct 15, 2026.
What sector is CAPR in?
Healthcare, in the Pharmaceuticals industry.
About Capricor Therapeutics
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
HQ: San Diego, CA231 employeesListed Jun 20, 2002capricor.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
